New onset of multiple keratoacanthomas and palmoplantar hyperkeratosis caused by the treatment of metastatic renal cell carcinoma with a new generation multi-kinase inhibitor.

The use of new generation multi-kinase inhibitors for the treatment of various malignancies has brought unique and previously unrecognised cutaneous reactions to the attention of dermatologists. We report the case of a patient with metastatic renal cell carcinoma who presented to our dermatology clinic with eruptive squamous cell carcinomas with keratoacanthomatous features and painless palmoplantar hyperkeratosis while taking sorafenib (Nexavar). Dermatological toxicity from sorafenib has been well described in the literature. Herein we describe a combination of unusual symptoms due to sorafenib.